Epithelial and Stromal Cell Urokinase Plasminogen Activator Receptor Expression Differentially Correlates with Survival in Rectal Cancer Stages B and C Patients

Urokinase plasminogen activator receptor (uPAR) has been proposed as a potential prognostic factor for colorectal cancer (CRC) patient survival. However, CRC uPAR expression remains controversial, especially regarding cell types where uPAR is overexpressed (e.g., epithelium (uPARE) or stroma-associated cells (uPARS)) and associated prognostic relevance. In this study, two epitope-specific anti-uPAR monoclonal antibodies (MAbs) could discriminate expression of uPARE from uPARS and were used to examine this association with survival of stages B and C rectal cancer (RC) patients. Using immunohistochemistry, MAbs #3937 and R4 were used to discriminate uPARE from uPARS respectively in the central and invasive frontal regions of 170 stage B and 179 stage C RC specimens. Kaplan-Meier and Cox regression analyses were used to determine association with survival. uPAR expression occurred in both epithelial and stromal compartments with differential expression observed in many cases, indicating uPARE and uPARS have different cellular roles. In the central and invasive frontal regions, uPARE was adversely associated with overall stage B survival (HR = 1.9; p = 0.014 and HR = 1.5; p = 0.031, respectively) reproducing results from previous studies. uPARS at the invasive front was associated with longer stage C survival (HR = 0.6; p = 0.007), reflecting studies demonstrating that macrophage peritumoural accumulation is associated with longer survival. This study demonstrates that different uPAR epitopes should be considered as being expressed on different cell types during tumour progression and at different stages in RC. Understanding how uPARE and uPARS expression affects survival is anticipated to be a useful clinical prognostic marker of stages B and C RC.

[1]  P. Chapuis,et al.  The relationship of survival to staging and grading of colorectal carcinoma: A prospective study of 503 cases , 1981, Cancer.

[2]  R C Newland,et al.  Terminology and classification of colorectal adenocarcinoma: the Australian clinico-pathological staging system. , 1983, The Australian and New Zealand journal of surgery.

[3]  P. Chapuis,et al.  The prognostic value of substaging colorectal carcinoma. A prospective study of 1117 cases with standardized pathology , 1987, Cancer.

[4]  M. Ploug,et al.  Cell‐induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2‐terminal domain of the urokinase receptor , 1991, FEBS letters.

[5]  J. Jass,et al.  Clinicopathological staging for colorectal cancer: An International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT) , 1991, Journal of gastroenterology and hepatology.

[6]  F. Blasi,et al.  In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion , 1991, The Journal of cell biology.

[7]  L. Kirkeby,et al.  Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer , 1994, Histopathology.

[8]  H. Ohtani,et al.  Expression of urokinase receptor in various stromal‐cell populations in human colon cancer: Immunoelectron microscopical analysis , 1995, International journal of cancer.

[9]  H. Ohtani,et al.  Stromal Expression of MMP‐9 and Urokinase Receptor Is Inversely Associated with Liver Metastasis and with Infiltrating Growth in Human Colorectal Cancer: A Novel Approach from Immune/Inflammatory Aspect , 1997, Japanese journal of cancer research : Gann.

[10]  Y. Morita,et al.  Urokinase type plasminogen activator receptor expression in colorectal neoplasms , 1998, Gut.

[11]  O. Dent,et al.  Local recurrence after curative excision of the rectum for cancer without adjuvant therapy: role of total anatomical dissection , 1999, The British journal of surgery.

[12]  H. Ohtani,et al.  Clinicopathologic significance of urokinase receptor‐ and mmp‐9‐positive stromal cells in human colorectal cancer: Functional multiplicity of matrix degradation on hematogenous metastasis , 2000, International journal of cancer.

[13]  P. Russell,et al.  Urokinase‐type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer‐specific survival and potential therapeutic targets , 2000, International journal of cancer.

[14]  U. Weidle,et al.  Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. , 2001, The Biochemical journal.

[15]  U. Weidle,et al.  Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. , 2001, The Biochemical journal.

[16]  H. Ohtani,et al.  Close Association between Fas Ligand (FasL; CD95L)‐positive Tumor‐associated Macrophages and Apoptotic Cancer Cells along Invasive Margin of Colorectal Carcinoma: A Proposal on Tumor‐Host Interactions , 2002, Japanese journal of cancer research : Gann.

[17]  P. Russell,et al.  Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer , 2003, Journal of surgical oncology.

[18]  A. Khorana,et al.  Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma , 2003, Cancer.

[19]  S. Takeno,et al.  Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. , 2003, Oncology reports.

[20]  C. D. de Bock,et al.  Clinical significance of urokinase‐type plasminogen activator receptor (uPAR) expression in cancer , 2004, Medicinal research reviews.

[21]  A. Ménez,et al.  Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide , 2005, The EMBO journal.

[22]  P. Oettgen,et al.  Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. , 2005, The Journal of clinical investigation.

[23]  R. Bates.  Colorectal Cancer Progression: Integrin alphavbeta6 and the Epithelial-Mesenchymal Transition (EMT) , 2005, Cell cycle.

[24]  P. Weinreb,et al.  Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy. , 2007, Journal of proteome research.

[25]  R. Palmqvist,et al.  High Macrophage Infiltration along the Tumor Front Correlates with Improved Survival in Colon Cancer , 2007, Clinical Cancer Research.

[26]  K. Chayama,et al.  Immunohistochemical molecular markers as predictors of curability of endoscopically resected submucosal colorectal cancer. , 2007, World journal of gastroenterology.

[27]  G. Høyer-Hansen,et al.  Urokinase receptor variants in tissue and body fluids. , 2007, Advances in clinical chemistry.

[28]  D. Shaw,et al.  An anti-urokinase plasminogen activator receptor (uPAR) antibody: crystal structure and binding epitope. , 2006, Journal of molecular biology.

[29]  G. Høyer-Hansen,et al.  Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. , 2008, Frontiers in bioscience : a journal and virtual library.

[30]  Jesper Eugen-Olsen,et al.  suPAR: The Molecular Crystal Ball , 2009, Disease markers.

[31]  B. Nielsen,et al.  Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor‐1 in colon cancer liver metastases , 2009, International journal of cancer.

[32]  E. van Marck,et al.  Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor‐1 in colon cancer liver metastases , 2009, International Journal of Cancer.

[33]  C. Craik,et al.  Antagonistic Anti-urokinase Plasminogen Activator Receptor (uPAR) Antibodies Significantly Inhibit uPAR-mediated Cellular Signaling and Migration* , 2010, The Journal of Biological Chemistry.

[34]  D. Shaw,et al.  An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. , 2010, Neoplasia.

[35]  C. Marshall,et al.  Regulation of cell signalling by uPAR , 2010, Nature Reviews Molecular Cell Biology.

[36]  Marco Erreni,et al.  Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer , 2011, Cancer Microenvironment.

[37]  L. Terracciano,et al.  Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. , 2010, Human pathology.

[38]  H. Im,et al.  Targeting the Urokinase Plasminogen Activator Receptor Inhibits Ovarian Cancer Metastasis , 2010, Clinical Cancer Research.

[39]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[40]  H. Nielsen,et al.  Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients , 2010, Acta oncologica.

[41]  Kimberly S. Butler,et al.  Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors , 2011, International journal of cancer.

[42]  M. Ploug,et al.  Conformational Regulation of Urokinase Receptor Function , 2011, The Journal of Biological Chemistry.

[43]  Ronan P. Murphy,et al.  The urokinase receptor interactome. , 2011, Current pharmaceutical design.

[44]  P. Quax,et al.  Clinical applications of the urokinase receptor (uPAR) for cancer patients. , 2011, Current pharmaceutical design.

[45]  S. Clarke,et al.  Overexpression of protein S100A4 is independently associated with overall survival in stage C colonic cancer but only in cytoplasm at the advancing tumour front , 2012, International Journal of Colorectal Disease.

[46]  M. Feuerer,et al.  Monocytes and Macrophages in Cancer: Development and Functions , 2013, Cancer Microenvironment.

[47]  P. Kuppen,et al.  Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study , 2014, BMC Cancer.

[48]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[49]  S. Rutella,et al.  The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation , 2014, Gut.

[50]  E. Nice,et al.  Correlations between Integrin ανβ6 Expression and Clinico-Pathological Features in Stage B and Stage C Rectal Cancer , 2014, PloS one.

[51]  T. O’Halloran,et al.  Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (αM) , 2014, PloS one.

[52]  C. Craik,et al.  Imaging the Urokinase Plasminongen Activator Receptor in Preclinical Breast Cancer Models of Acquired Drug Resistance , 2014, Theranostics.

[53]  H. Nielsen,et al.  Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer , 2014, Cancer medicine.